These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 34182224)

  • 1. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
    Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A
    Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients.
    Bridel C; Verberk IMW; Heijst JJA; Killestein J; Teunissen CE
    Mult Scler Relat Disord; 2021 Jan; 47():102666. PubMed ID: 33291033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
    Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
    Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.
    Hegen H; Berek K; Bsteh G; Auer M; Altmann P; Di Pauli F; Grams A; Milosavljevic D; Ponleitner M; Poskaite P; Schnabl C; Wurth S; Zinganell A; Berger T; Walde J; Deisenhammer F
    EBioMedicine; 2023 May; 91():104573. PubMed ID: 37086651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Srpova B; Uher T; Hrnciarova T; Barro C; Andelova M; Michalak Z; Vaneckova M; Krasensky J; Noskova L; Havrdova EK; Kuhle J; Horakova D
    Mult Scler; 2021 Jan; 27(1):52-60. PubMed ID: 31961243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
    Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients.
    Valentino P; Malucchi S; Bava CI; Martire S; Capobianco M; Malentacchi M; Sperli F; Oggero A; Di Sapio A; Bertolotto A
    Mult Scler Relat Disord; 2023 Sep; 77():104893. PubMed ID: 37481820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases.
    Ziaei A; Nasr Z; Hart J; Francisco C; Rutatangwa A; Leppert D; Kuhle J; Flanagan E; Waubant E
    Mult Scler Relat Disord; 2023 Jun; 74():104704. PubMed ID: 37031551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
    Bjornevik K; Munger KL; Cortese M; Barro C; Healy BC; Niebuhr DW; Scher AI; Kuhle J; Ascherio A
    JAMA Neurol; 2020 Jan; 77(1):58-64. PubMed ID: 31515562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years.
    Friedova L; Motyl J; Srpova B; Oechtering J; Barro C; Vodehnalova K; Andelova M; Noskova L; Fialová L; Havrdova EK; Horakova D; Benedict RH; Kuhle J; Uher T
    Mult Scler Relat Disord; 2020 Nov; 46():102534. PubMed ID: 33032055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
    Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.